Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Biohaven Completes Enrollment for Phase 2 Obesity Trial with Taldefgrobep Alfa Biohaven has completed enrollment for a Phase 2 obesity study using Taldefgrobep Alfa, aiming for significant weight loss and muscle gain.

Biohaven Completes Enrollment for Phase 2 Obesity Trial with Taldefgrobep Alfa #US #Biohaven #New_Haven #Taldefgrobep_Alfa #Obesity_Study

Thiard News@F4F

@newsen.bsky.social

1 month ago

Biohaven Reports Key Developments and Financial Results for 2025 Biohaven shares recent advancements in their clinical programs and financial outcomes for 2025, highlighting key strategies and expected milestones.

Biohaven Reports Key Developments and Financial Results for 2025 #United_States #Biohaven #New_Haven #IgG_MoDE #Kv7_Ion_Channel

Thiard News@F4F

@newsen.bsky.social

2 months ago

Biohaven's Breakthrough Portfolio Achievements and Promising Clinical Data Unveiled at J.P. Morgan Healthcare Conference At the J.P. Morgan Healthcare Conference, Biohaven showcased significant progress in their clinical programs, highlighting innovative new treatments for serious diseases.

Biohaven's Breakthrough Portfolio Achievements and Promising Clinical Data Unveiled at J.P. Morgan Healthcare Conference #USA #Biohaven #New_Haven #MODE #TRAP

Thiard News@F4F

@newsen.bsky.social

2 months ago

Biohaven CEO Vlad Coric to Speak at J.P. Morgan Healthcare Conference in January 2026 Biohaven Ltd. will be represented by CEO Vlad Coric at the upcoming J.P. Morgan Healthcare Conference, discussing advancements and innovations in therapies.

Biohaven CEO Vlad Coric to Speak at J.P. Morgan Healthcare Conference in January 2026 #United_States #San_Francisco #Biohaven #Healthcare_Conference #Vlad_Coric

Thiard News@F4F

@newsen.bsky.social

3 months ago

Biohaven Unveils Promising Clinical Data for BHV-1510 at ESMO 2025 Immuno-Oncology Congress Biohaven Ltd. reveals compelling clinical safety and efficacy data for its promising drug BHV-1510, presented at ESMO 2025. This innovative treatment may revolutionize cancer therapy.

Biohaven Unveils Promising Clinical Data for BHV-1510 at ESMO 2025 Immuno-Oncology Congress #London #United_Kingdom #Biohaven #Cemiplimab #BHV-1510

Thiard News@F4F

@newsen.bsky.social

4 months ago

Biohaven Reports Financial Results for Q3 2025 and Strategic Developments in Drug Pipeline Biohaven Ltd. shared its financial results for Q3 2025, highlighting advancements in clinical programs and a focus on optimizing resources for innovative therapies.

Biohaven Reports Financial Results for Q3 2025 and Strategic Developments in Drug Pipeline #USA #Biohaven #New_Haven #BHVN #Opakalim

Thiard News@F4F

@newsen.bsky.social

5 months ago

FDA Responds to Biohaven's VYGLXIA Application for Spinocerebellar Ataxia Treatment Biohaven's VYGLXIA (troriluzole) application for treating Spinocerebellar Ataxia faced a complete response from the FDA, igniting concerns.

FDA Responds to Biohaven's VYGLXIA Application for Spinocerebellar Ataxia Treatment #United_States #Biohaven #New_Haven #Spinocerebellar_Ataxia #VYGLXIA

Thiard News@F4F

@newsen.bsky.social

7 months ago

Investors in Biohaven Ltd. Urged to Take Action on Fraud Lawsuit The Schall Law Firm calls on Biohaven Ltd. investors to join a class action lawsuit over securities fraud. Ensure your rights are protected.

Investors in Biohaven Ltd. Urged to Take Action on Fraud Lawsuit #USA #Los_Angeles #Schall_Law_Firm #Securities_Fraud #Biohaven

Thiard News@F4F

@newsen.bsky.social

7 months ago

Investors of Biohaven Ltd. Have Opportunity to Lead Securities Fraud Lawsuit Biohaven Ltd. investors with losses exceeding $100K may file to lead a class action lawsuit regarding alleged securities fraud. Learn how to join.

Investors of Biohaven Ltd. Have Opportunity to Lead Securities Fraud Lawsuit #USA #New_York #Securities_Fraud #Rosen_Law_Firm #Biohaven

Thiard News@F4F

@newsen.bsky.social

7 months ago

Opportunity for Investors to Lead Securities Fraud Class Action Against Biohaven Ltd. (BHVN) Investors who suffered significant losses in Biohaven Ltd. may now file to lead a securities fraud class action lawsuit. Contact the law firm for more.

Opportunity for Investors to Lead Securities Fraud Class Action Against Biohaven Ltd. (BHVN) #USA #Securities_Fraud #Bensalem #Biohaven #BHVN

Thiard News@F4F

@newsen.bsky.social

7 months ago

Faruqi & Faruqi Highlights Important Class Action for Biohaven Investors Ahead of September 2025 Deadline Faruqi & Faruqi reminds Biohaven Ltd. shareholders of the class action lawsuit and the September 12, 2025, lead plaintiff deadline targeting potential claims.

Faruqi & Faruqi Highlights Important Class Action for Biohaven Investors Ahead of September 2025 Deadline #USA #New_York #Securities_Law #Biohaven #Faruqi_&_Faruqi

Thiard News@F4F

@newsen.bsky.social

7 months ago

Shareholder Alert: Faruqi & Faruqi Investigates Biohaven Securities Claims Faruqi & Faruqi, a recognized securities law firm, is probing allegations concerning Biohaven Ltd. claims. Investors are urged to act swiftly.

Shareholder Alert: Faruqi & Faruqi Investigates Biohaven Securities Claims #United_States #New_York #Biohaven #Faruqi_&_Faruqi #BHVN

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

Click Subscribe #Biohaven #FDA #PharmaNews #RareDiseases #StockMarket

Thiard News@F4F

@newsen.bsky.social

7 months ago

Investors of Biohaven Ltd. Can Lead a Securities Fraud Case Following Misconduct Biohaven Ltd. investors from the March 2023 to May 2025 period can seek compensation through a class action lawsuit, with a lead plaintiff deadline set for September 12, 2025.

Investors of Biohaven Ltd. Can Lead a Securities Fraud Case Following Misconduct #United_States #New_York #Class_Action #Securities_Fraud #Biohaven

Thiard News@F4F

@newsen.bsky.social

7 months ago

Pomerantz Law Firm Initiates Class Action Against Biohaven Ltd Due to Alleged Securities Violations Pomerantz Law Firm has filed a class action lawsuit against Biohaven Ltd, alleging securities law violations related to their drug, troriluzole. Investors may recover damages.

Pomerantz Law Firm Initiates Class Action Against Biohaven Ltd Due to Alleged Securities Violations #United_States #New_York #Class_Action #Biohaven #Pomerantz_Law

Thiard News@F4F

@newsen.bsky.social

7 months ago

Biohaven Announces Promising Financial Results and Future Developments in Innovative Therapies Biohaven Ltd. shares significant Q2 2025 financial results, showcasing advancements in therapies for conditions like neurodegeneration and immunology.

Biohaven Announces Promising Financial Results and Future Developments in Innovative Therapies #United_States #Biohaven #New_Haven #BHV-8000 #VYGLXIA

Thiard News@F4F

@newsen.bsky.social

7 months ago

Faruqi & Faruqi Investigates Biohaven: Deadline Approaching for Investors to Act Faruqi & Faruqi, LLP is investigating potential legal claims for Biohaven investors. The firm urges affected parties to take action before the upcoming deadline.

Faruqi & Faruqi Investigates Biohaven: Deadline Approaching for Investors to Act #USA #New_York #Securities_Law #Biohaven #Faruqi_&_Faruqi

Thiard News@F4F

@newsen.bsky.social

8 months ago

Investors of Biohaven Ltd. Find Hope for Leading Fraud Lawsuit Biohaven Ltd. investors with losses due to recent regulatory issues now have a chance to lead a securities fraud lawsuit against the Company as action proceeds.

Investors of Biohaven Ltd. Find Hope for Leading Fraud Lawsuit #None #Securities_Fraud #Biohaven #BHVN

Thiard News@F4F

@newsen.bsky.social

8 months ago

Investors Alert: Join the Biohaven Ltd. Securities Fraud Lawsuit The Schall Law Firm is reminding Biohaven Ltd. investors about a class action lawsuit related to securities fraud and is inviting affected shareholders to join.

Investors Alert: Join the Biohaven Ltd. Securities Fraud Lawsuit #USA #Los_Angeles #Schall_Law_Firm #Securities_Fraud #Biohaven

Thiard News@F4F

@newsen.bsky.social

8 months ago

Biohaven Investors Alert: Legal Options for Those Facing Losses Over $50,000 Faruqi & Faruqi, LLP is probing legal options for Biohaven investors with losses over $50,000. Contact them to explore your options before the deadline.

Biohaven Investors Alert: Legal Options for Those Facing Losses Over $50,000 #United_States #New_York #Lawsuit #Biohaven #Faruqi_&_Faruqi

Thiard News@F4F

@newsen.bsky.social

10 months ago

Biohaven Announces Enrollment of First Patient in Parkinson's Disease Trial with Innovative BHV-8000 Treatment Biohaven Ltd. kicks off a pivotal Phase 2/3 trial for BHV-8000, a new therapy targeting neuroinflammation in early Parkinson's disease, marking a crucial step in novel treatment development.

Biohaven Announces Enrollment of First Patient in Parkinson's Disease Trial with Innovative BHV-8000 Treatment #United_States #Biohaven #New_Haven #Parkinson's_Disease #BHV-8000

Thiard News@F4F

@newsen.bsky.social

10 months ago

Biohaven Unveils Breakthrough Data from MoDE and TRAP Platforms at R&D Day Biohaven showcased revolutionary TRAP Degrader data at R&D Day, revealing over 80% reduction in Gd-IgA1 for treating IgA Nephropathy with BHV-1400.

Biohaven Unveils Breakthrough Data from MoDE and TRAP Platforms at R&D Day #USA #Biohaven #New_Haven #IgA_nephropathy #BHV-1400

Thiard News@F4F

@newsen.bsky.social

10 months ago

Biohaven Reveals Promising Results of Oncology Programs Featuring Novel Antibody Drug Conjugates Biohaven shared recent developments in its oncology efforts, showcasing the potential of innovative antibody drug conjugates targeting various tumors, including promising clinical findings.

Biohaven Reveals Promising Results of Oncology Programs Featuring Novel Antibody Drug Conjugates #USA #Cancer_Treatments #Biohaven #New_Haven #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

10 months ago

FDA Extends PDUFA Date for Biohaven to Review Troriluzole for SCA Treatment The FDA has extended the PDUFA date for Biohaven's Troriluzole application aimed at treating Spinocerebellar Ataxia, a rare neurodegenerative disease.

FDA Extends PDUFA Date for Biohaven to Review Troriluzole for SCA Treatment #United_States #Biohaven #New_Haven #Troriluzole #Biohaven_Ltd

Thiard News@F4F

@newsen.bsky.social

10 months ago

Biohaven Achieves Significant Milestones in First Quarter 2025 Amidst Economic Challenges Biohaven Ltd. reports promising financial results for Q1 2025, highlighting significant funding agreements and ongoing clinical developments amid economic uncertainties.

Biohaven Achieves Significant Milestones in First Quarter 2025 Amidst Economic Challenges #United_States #Biohaven #New_Haven #Troriluzole #Oberland_Capital

Thiard News@F4F

@newsen.bsky.social

11 months ago

Biohaven Secures Major Investment from Oberland Capital to Enhance Development of Troriluzole for Rare Diseases Biohaven Ltd. has announced a substantial investment of up to $600 million from Oberland Capital, aimed at furthering the development of their innovative therapy, Troriluzole, targeting rare genetic diseases.

Biohaven Secures Major Investment from Oberland Capital to Enhance Development of Troriluzole for Rare Diseases #United_States #Biohaven #New_Haven #BHVN #Oberland_Capital

Profit Trading USA

@profittradingusa.bsky.social

11 months ago

Click Subscribe #Biohaven #Pharma #Dazluma #StockMarket #Investing

Thiard News@F4F

@newsen.bsky.social

1 year ago

Biohaven Showcases Promising Neuroscience Innovations at AAN 2025 Annual Meeting At the AAN 2025 Annual Meeting, Biohaven will unveil 13 groundbreaking abstracts, showcasing advancements in neuroscience therapies aimed at neurological disorders.

Biohaven Showcases Promising Neuroscience Innovations at AAN 2025 Annual Meeting #USA #San_Diego #Biohaven #Neurology #AAN2025

Thiard News@F4F

@newsen.bsky.social

1 year ago

Biohaven Reports Key Developments and Financial Results for 2024, Highlighting Innovative Drug Applications Biohaven recently shared updates on its success in drug applications and their financial results for 2024, emphasizing the innovation in their treatments.

Biohaven Reports Key Developments and Financial Results for 2024, Highlighting Innovative Drug Applications #USA #Biohaven #New_Haven #BHV-1300 #Troriluzole

Thiard News@F4F

@newsen.bsky.social

1 year ago

Biohaven's BHV-1300 Shows Promise in Reducing Total IgG Levels for Autoimmune Disorders Biohaven's new drug, BHV-1300, achieves remarkable reductions in IgG levels, highlighting its potential for treating autoimmune diseases like Graves' disease.

Biohaven's BHV-1300 Shows Promise in Reducing Total IgG Levels for Autoimmune Disorders #USA #Biohaven #New_Haven #BHV-1300 #Graves'_Disease